Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preemptive Treatment Strategies for Panitumumab-Mediated Skin Toxicity in Colorectal Cancer
NCT01668498Phase 2Completed
- Sponsor
- AIO-Studien
- Start
- May 2011
- Primary completion
- Jan 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of erythromycin in Skin Toxicity (2 arms), sponsored by AIO-Studien. Primary endpoint: Percentage of patients developing no skin toxicity >= grade 2 at 8 weeks. Started May 2011; status: completed.
02
Drugs
erythromycin
03
Conditions
Skin Toxicity
Beyond the preview
Go deeper on NCT01668498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01668498.